Log in

Relevant bibliographies by topics / Ioflupano / Journal articles

Journal articles on the topic 'Ioflupano'

To see the other types of publications on this topic, follow the link: Ioflupano.

Author: Grafiati

Published: 9 March 2023

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ioflupano.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Serrano Vicente, J., L. García Bernardo, C. Durán Barquero, A. Constantino Silva, J. R. Infante de la Torre, M. L. Domínguez Grande, J. I. Rayo Madrid, R. Sánchez Sánchez, and C. Durán Herrera. "Valor predictivo negativo del SPECT con Ioflupano 123I en los trastornos del movimiento." Revista Española de Medicina Nuclear 28, no. 1 (February 2009): 2–5. http://dx.doi.org/10.1016/s0212-6982(09)70207-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Díaz Platas, Lucía, Stefan Prado Wohlwend, Mónica Romero Otero, Alba Iniesta Medel, and Luis Ramudo Cela. "Relación entre la pureza radioquímica del 123i-ioflupano y la captación extracraneal (tiroidea y parotídea)." Ars Pharmaceutica (Internet) 56, no. 4 (December 2015): 225–30. http://dx.doi.org/10.4321/s2340-98942015000400006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Puñal Riobóo, J., L. Varela Lema, A. Serena Puig, and A. Ruano-Ravina. "Efectividad del 123I-ioflupano (DaTSCAN©) en el diagnóstico de síndromes parkinsonianos. Una revisión sistemática." Revista Española de Medicina Nuclear 26, no. 6 (December 2007): 375–84. http://dx.doi.org/10.1157/13112366.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Durán Ferreras, Eduardo, and Andrés Durán Ferreras. "Utilidad de la SPECT con 123I-ioflupano (DaT-scan) en el parkinsonismo inducido por fármacos." Revista de Neurología 52, no. 06 (2011): 382. http://dx.doi.org/10.33588/rn.5206.2010757.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

García Vicente, A. M., J. Vaamonde Cano, A. Soriano Castrejón, C. Martínez Delgado, P. Talavera Rubio, V. M. Poblete García, S. Ruiz Solís, S. Rodado Marina, and M. Cortés Romera. "SPECT con ioflupano I-123 en la catalogación de pacientes con síndrome parkinsoniano y vasculopatía cerebral." Revista Española de Medicina Nuclear 24, no. 6 (December 2005): 392–403. http://dx.doi.org/10.1016/s0212-6982(05)74184-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Serrano Vicente, J., L. García Bernardo, C. Durán Barquero, A. Constantino Silva, J. R. Infante de la Torre, M. L. Domínguez Grande, J. I. Rayo Madrid, R. Sánchez Sánchez, and C. Durán Herrera. "Valor predictivo negativo de la SPECT con ioflupano-I-123 en los trastornos del movimiento (réplica)." Revista Española de Medicina Nuclear 28, no. 5 (September 2009): 267–68. http://dx.doi.org/10.1016/j.remn.2009.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

García-Gómez, F. J., D. García-Solís, F. J. Luis-Simón, V. A. Marín-Oyaga, F. Carrillo, P. Mir, and R. J. Vázquez-Albertino. "Elaboración de una plantilla de SPM para la normalización de imágenes de SPECT con 123I-Ioflupano." Revista Española de Medicina Nuclear e Imagen Molecular 32, no. 6 (November 2013): 350–56. http://dx.doi.org/10.1016/j.remn.2013.02.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

García Vicente, A. M., J. Vaamonde Cano, V. M. Poblete García, S. Rodado Marina, M. Cortés Romera, S. Ruiz Solís, R. Ibáñez Alonso, and A. Soriano Castrejón. "Utilidad de la imagen de transportadores de dopamina (SPECT cerebral con ioflupano I-123) en la valoración de los trastornos del movimiento." Revista Española de Medicina Nuclear 23, no. 4 (January 2004): 245–52. http://dx.doi.org/10.1016/s0212-6982(04)72294-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Soriano Castrejón, Angel, Ana María García Vicente, Montserrat Cortés Romera, Julia Vaamonde Cano, Sonia Rodado Marina, Victor Manuel Poblete García, Sebastián Ruiz Solís, and María del Prado Talavera Rubio. "123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders." Brazilian Archives of Biology and Technology 48, spe2 (October 2005): 115–26. http://dx.doi.org/10.1590/s1516-89132005000700017.

Full text

Abstract:

123-I Ioflupane (Datscan®) presynaptic imaging has been shown to have a significant utility in the assessment of patients with movement disorders 123-I Ioflupane SPECT is able to distinguish between Parkinson’s disease (PD) and other forms of parkinsonism without degeneration of the nigrostriatal pathway, including a common movement disorder such as essential tremor, and to assess disease progression in PD and other neurodegenerative disorders involving the substantia nigra.

APA, Harvard, Vancouver, ISO, and other styles

10

Antonini, Angelo, and Giorgio L. Colombo. "Il ruolo della SPECT in associazione a iofupane nella diagnosi della Malattia di Parkinson: i risultati di un’esperienza." Farmeconomia. Health economics and therapeutic pathways 3, no. 3 (September 15, 2002): 125–33. http://dx.doi.org/10.7175/fe.v3i3.750.

Full text

Abstract:

According to the latest data, in Italy 200.000 patients are affected by the Parkinson’s Disease, and the trend is bound to go up. Generally the diagnosis, crucial in this pathology, is based on the clinic observation. But the absence of typical signs or symptoms increases the possibility of diagnostic mistakes. Ioflupane (DATSCAN ®) is a new diagnostic agent indicated for detecting loss of functional dopaminergic neuron terminals in the striatum of patients with clinically uncertain Parkinsonian Syndromes. The use of Ioflupane (DATSCAN ®) in association with the single-photon emission computed tomography (SPECT) allows to improve the diagnosis. Applying systematically this diagnostic model could cause a significant reduction in hospedalization cost, with less trouble for patients and a better quality of life. Aim of this study is to show the clinical and economic consequences of the use of Ioflupane (DATSCAN â) in association with SPECT as a new standard for the diagnosis of Parkinson’s Disease, considering the perspective of the National Heath System (NHS) and a single hospital structure.

APA, Harvard, Vancouver, ISO, and other styles

11

Nuvoli, Susanna, Giovanna Tanda, Maria L. Stazza, Barbara Palumbo, Viviana Frantellizzi, Giuseppe De Vincentis, Angela Spanu, and Giuseppe Madeddu. "123I-Ioflupane SPECT and 18F-FDG PET Combined Use in the Characterization of Movement and Cognitive Associated Disorders in Neurodegenerative Diseases." Current Alzheimer Research 18, no. 3 (August 6, 2021): 196–207. http://dx.doi.org/10.2174/1567205018666210608112302.

Full text

Abstract:

Background: Both movement (MD) and cognitive (CD) disorders can occur associated in some neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). Objective: We further investigated the usefulness of 123I-Ioflupane SPECT and 18F-FDG PET combined use in patients with these disorders in the early stage. Methods: We retrospectively enrolled twenty-five consecutive patients with MD and CD clinical symptoms of recent appearance. All patients had undergone neurologic examination, neuropsychological tests, and magnetic resonance imaging. 123I-Ioflupane SPECT was performed in all cases, followed by 18F-FDG PET two weeks later. In the two procedures, both qualitative (QL) and quantitative (QN) image analyses were determined. Results: In patients with both 123I-Ioflupane SPECT and 18F-FDG PET pathologic data, associated dopaminergic and cognitive impairments were confirmed in 56% of cases. Pathologic SPECT with normal PET in 16% of cases could diagnose MD and exclude an associated CD, despite clinical symptoms. On the contrary, normal SPECT with pathologic PET in 28% of cases could exclude basal ganglia damage while confirming CD. QN 123I-Ioflupane SPECT analysis showed better performance than QL since QN correctly characterized two cases of MD with normal QL. Moreover, correct classification of normal metabolism was made only by QN analysis of 18F-FDG PET in four cases, despite suspect areas of hypometabolism at QL. Conclusion: The combined use of these imaging procedures proved a reliable diagnostic tool to accurately identify and characterize MD and CD in early stage. QN analysis was effective in supporting QL evaluation, and its routine use is suggested, especially with inconclusive QL.

APA, Harvard, Vancouver, ISO, and other styles

12

Warhadpande, Devdutta S., Jiayan Huo, William A. Libling, Carol Stuehm, Bijan Najafi, Scott Sherman, Hong Lei, Janet Meiling Roveda, and Phillip H. Kuo. "Pilot Study for Correlation of Heart Rate Variability and Dopamine Transporter Brain Imaging in Patients with Parkinsonian Syndrome." Sensors 22, no. 13 (July 5, 2022): 5055. http://dx.doi.org/10.3390/s22135055.

Full text

Abstract:

Background: Parkinsonian syndrome (PS) is a broad category of neurodegenerative movement disorders that includes Parkinson disease, multiple system atrophy (MSA), progressive supranuclear palsy, and corticobasal degeneration. Parkinson disease (PD) is the second most common neurodegenerative disorder with loss of dopaminergic neurons of the substantia nigra and, thus, dysfunction of the nigrostriatal pathway. In addition to the motor symptoms of bradykinesia, rigidity, tremors, and postural instability, nonmotor symptoms such as autonomic dysregulation (AutD) can also occur. Heart rate variability (HRV) has been used as a measure of AutD and has shown to be prognostic in diseases such as diabetes mellitus and cirrhosis, as well as PD. I-123 ioflupane, a gamma ray-emitting radiopharmaceutical used in single-photon emission computed tomography (SPECT), is used to measure the loss of dopaminergic neurons in PD. Through the combination of SPECT and HRV, we tested the hypothesis that asymmetrically worse left-sided neuronal loss would cause greater AutD. Methods: 51 patients were enrolled on the day of their standard of care I-123 ioflupane scan for the work-up of possible Parkinsonian syndrome. Demographic information, medical and medication history, and ECG data were collected. HRV metrics were extracted from the ECG data. I-123 ioflupane scans were interpreted by a board-certified nuclear radiologist and quantified by automated software to generate striatal binding ratios (SBRs). Statistical analyses were performed to find correlations between the HRV and SPECT parameters. Results: 32 patients were excluded from the final analysis because of normal scans, prior strokes, cardiac disorders and procedures, or cancer. Abnormal I-123 ioflupane scans were clustered using T-SNE, and one-way ANOVA was performed to compare HRV and SBR parameters. The analysis was repeated after the exclusion of patients taking angiotensin-converting enzyme inhibitors, given the known mechanism on autonomic function. Subsequent analysis showed a significant difference between the high-frequency domains of heart rate variability, asymmetry of the caudate SBR, and putamen-to-caudate SBR. Conclusion: Our results support the hypothesis that more imbalanced (specifically worse left-sided) neuronal loss results in greater AutD.

APA, Harvard, Vancouver, ISO, and other styles

13

Paghera, Barbara, Federico Caobelli, and Raffaele Giubbini. "123I-Ioflupane SPECT in Fahr Disease." Journal of Neuroimaging 23, no. 1 (March 16, 2011): 157–58. http://dx.doi.org/10.1111/j.1552-6569.2011.00581.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Pahuja, Gunjan, T. N. Nagabhushan, and Bhanu Prasad. "Early Detection of Parkinson’s Disease by Using SPECT Imaging and Biomarkers." Journal of Intelligent Systems 29, no. 1 (March 27, 2019): 1329–44. http://dx.doi.org/10.1515/jisys-2018-0261.

Full text

Abstract:

Abstract Precise and timely diagnosis of Parkinson’s disease is important to control its progression among subjects. Currently, a neuroimaging technique called dopaminergic imaging that uses single photon emission computed tomography (SPECT) with 123I-Ioflupane is popular among clinicians for detecting Parkinson’s disease in early stages. Unlike other studies, which consider only low-level features like gray matter, white matter, or cerebrospinal fluid, this study explores the non-linear relation between different biomarkers (SPECT + biological) using deep learning and multivariate logistic regression. Striatal binding ratios are obtained using 123I-Ioflupane SPECT scans from four brain regions which are further integrated with five biological biomarkers to increase the diagnostic accuracy. Experimental results indicate that this investigated approach can differentiate subjects with 100% accuracy. The obtained results outperform the ones reported in the literature. Furthermore, logistic regression model has been developed for estimating the Parkinson’s disease onset probability. Such models may aid clinicians in diagnosing this disease.

APA, Harvard, Vancouver, ISO, and other styles

15

Ceulemans, Gaetane, Douwe Verdries, Jan Versijpt, Christian Vanhove, and Hendrik Everaert. "Extrastriatal uptake on 123I-ioflupane brain SPECT." European Journal of Nuclear Medicine and Molecular Imaging 37, no. 5 (February 4, 2010): 1048. http://dx.doi.org/10.1007/s00259-009-1369-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Mouraeff, Yvan, Karim Farid, Xavier Poullias, Ana Goncalves, Slavomir Petras, and Nadine Caillat-Vigneron. "Thyroid protection before 123I-ioflupane (DaTSCAN) imaging." European Journal of Nuclear Medicine and Molecular Imaging 38, no. 4 (January 28, 2011): 786–87. http://dx.doi.org/10.1007/s00259-010-1726-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Dellavedova, Luca, Andrea Giorgetti, and Lorenzo Stefano Maffioli. "Impact of 123I-Ioflupane SPECT in Patient Management." Clinical Nuclear Medicine 41, no. 3 (March 2016): e154-e155. http://dx.doi.org/10.1097/rlu.0000000000001018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Sato, Kenichiro, Ayumi Hida, Masashi Kameyama, Miyako Morooka, and Sousuke Takeuchi. "Reduced 123I Ioflupane Binding in Bilateral Diabetic Chorea." Clinical Nuclear Medicine 41, no. 6 (June 2016): 481–82. http://dx.doi.org/10.1097/rlu.0000000000001202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Lange, Catharina, Anita Seese, Sarah Schwarzenböck, Karen Steinhoff, Bert Umland-Seidler, Bernd J. Krause, Winfried Brenner, et al. "CT-Based Attenuation Correction in I-123-Ioflupane SPECT." PLoS ONE 9, no. 9 (September 30, 2014): e108328. http://dx.doi.org/10.1371/journal.pone.0108328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Kang, Arnold, and Satoshi Minoshima. "123I-Ioflupane SPECT Findings of Pantothenate Kinase–Associated Neurodegeneration." Clinical Nuclear Medicine 39, no. 9 (September 2014): 849–51. http://dx.doi.org/10.1097/rlu.0000000000000409.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Carrasco García de León, Sira, Juan Pablo Cabello, Ramón Ortiz, and Julia Vaamonde. "Parkinsonism Associated with Pathological 123I-FP-CIT SPECT (DaTSCAN) Results as the Initial Manifestation of Sporadic Creutzfeldt-Jakob Disease." Case Reports in Neurological Medicine 2018 (May 31, 2018): 1–3. http://dx.doi.org/10.1155/2018/5157275.

Full text

Abstract:

Sporadic Creutzfeldt-Jakob disease (sCJD) is a type of progressive, subacute encephalopathy associated with spongiform degeneration of the central nervous system. sCJD includes a broad and heterogeneous spectrum of clinical variants, but extrapyramidal symptoms and signs at disease onset were rarely reported. We describe a case of unilateral parkinsonism associated with pathological 123I-ioflupane SPECT (DaTSCAN) results as the initial manifestation of M129V subtype sCJD patient. To the best of our knowledge, only 2 cases of Creutzfeldt-Jakob disease demonstrating nigrostriatal dopaminergic deficits in vivo using DaTSCAN have been published in the literature.

APA, Harvard, Vancouver, ISO, and other styles

22

Baghdadi, Yaser, Se Jin Anh, Allan Brook, Renee Moadel, and Leonard M. Freeman. "Unilateral Absence of the Basal Ganglia on 123I-Ioflupane DaTScan." Clinical Nuclear Medicine 44, no. 10 (October 2019): 842–43. http://dx.doi.org/10.1097/rlu.0000000000002743.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Petyt, G., A. Kreisler, F. Demailly, A. Olivier, L. Defebvre, and F. Semah. "Undetectable specific striatal [123I]-ioflupane binding in patients with parkinsonism." Journal of the Neurological Sciences 341, no. 1-2 (June 2014): 167–71. http://dx.doi.org/10.1016/j.jns.2014.04.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Hinnell, Claire, Muriel Buxton-Thomas, Naomi Sibtain, and Michael Samuel. "Striatal 123I-Ioflupane SPECT abnormality in sporadic Creutzfeldt–Jakob disease." Journal of Neurology 258, no. 5 (December 21, 2010): 948–50. http://dx.doi.org/10.1007/s00415-010-5860-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Manoharan, P., S. Jamieson, and R. F. Bury. "Initial clinical experience with [123I]ioflupane scintigraphy in movement disorders." Clinical Radiology 62, no. 5 (May 2007): 463–71. http://dx.doi.org/10.1016/j.crad.2006.10.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Gaig, Carles, Maria José Martí, Eduardo Tolosa, Francesc Valldeoriola, Pilar Paredes, Francisco Juan Lomeña, and Fernando Nakamae. "123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism." Movement Disorders 21, no. 11 (2006): 1994–98. http://dx.doi.org/10.1002/mds.21062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Rahman, Mahmudur G. M., Muhammad M. Islam, Tetsuya Tsujikawa, and Hidehiko Okazawa. "A Novel Automatic Approach for Calculation of the Specific Binding Ratio in [I-123]FP-CIT SPECT." Diagnostics 10, no. 5 (May 9, 2020): 289. http://dx.doi.org/10.3390/diagnostics10050289.

Full text

Abstract:

A fully automatic method for specific binding ratio (SBR) calculation in [123I]ioflupane single-photon emission computed tomography (SPECT) studies was proposed by creating volumes of interest of the striatum (VOIst) and reference region (VOIref) without manual handling to avoid operator-induced variability. The study involved 105 patients (72 ± 10 years) suspected of parkinsonian syndrome (PS) who underwent [123I]ioflupane SPECT. The 200 images from our previous study were used for evaluation and validation of the new program. All patients were classified into PS and non-PS groups according to the results of clinical follow-up. A trapezoidal volume of interest (VOIt) containing all striatal intensive counts was created automatically, followed by VOIst setting using the previous method. SBR values were calculated from the mean values of VOIst and VOIref determined by the whole brain outside of VOIt. The low count voxels in the VOIref were excluded using an appropriate threshold. The SBR values from the new method were compared with the previous semi-automatic method and the Tossici–Bolt (TB) method. The SBRs from the semi- and fully automatic methods showed a good linear correlation (r > 0.98). The areas under the curves (AUCs) of receiver operating characteristic analysis showed no significant difference between the two methods for both our previous (AUC > 0.99) and new (AUC > 0.95) data. The diagnostic accuracy of the two methods showed similar results (>92%), and both were better than the TB method. The proposed method successfully created the automatic VOIs and calculated SBR rapidly (9 ± 1 s/patient), avoiding operator-induced variability and providing objective SBR results.

APA, Harvard, Vancouver, ISO, and other styles

28

Takahashi, Masaki, Shoichi Toki, Yukitaka Yamashita, and Akihiro Kaneko. "Evaluation of Early-phase Biodistribution in ¹²³I-ioflupane SPECT." Japanese Journal of Radiological Technology 73, no. 9 (2017): 731–36. http://dx.doi.org/10.6009/jjrt.2017_jsrt_73.9.731.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Banks, Kevin P., Justin G. Peacock, Michael N. Clemenshaw, and Phillip H. Kuo. "Optimizing the Diagnosis of Parkinsonian Syndromes With 123I-Ioflupane Brain SPECT." American Journal of Roentgenology 213, no. 2 (August 2019): 243–53. http://dx.doi.org/10.2214/ajr.19.21088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Badoud, Simon, Dimitri Van De Ville, Nicolas Nicastro, Valentina Garibotto, Pierre R. Burkhard, and Sven Haller. "Discriminating among degenerative parkinsonisms using advanced 123 I-ioflupane SPECT analyses." NeuroImage: Clinical 12 (February 2016): 234–40. http://dx.doi.org/10.1016/j.nicl.2016.07.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Hayashi, Toshiyuki, Masahiro Mishina, Masanori Sakamaki, Yuki Sakamoto, Satoshi Suda, and Kazumi Kimura. "Effect of brain atrophy in quantitative analysis of 123I-ioflupane SPECT." Annals of Nuclear Medicine 33, no. 8 (May 28, 2019): 579–85. http://dx.doi.org/10.1007/s12149-019-01367-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Manoharan, P., S. Jamieson, and R. Bury. "A15 Initial clinical experience with 123I ioflupane scintigraphy in movement disorders." Nuclear Medicine Communications 26, no. 1 (January 2005): 76. http://dx.doi.org/10.1097/00006231-200501000-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Staff, R. T., A. D. Murray, T. S. Ahearn, C. E. Counsell, K. Taylor, K. Wilson, and H. G. Gemmell. "P38 FPCIT.NET: A WEB BASED ARCHIVE FOR USE WITH 123I IOFLUPANE." Nuclear Medicine Communications 26, no. 3 (March 2005): 294. http://dx.doi.org/10.1097/00006231-200503000-00110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Staff, R. T., A. D. Murray, T. S. Ahearn, C. E. Counsell, K. Taylor, K. Wilson, and H. G. Gemmell. "P38 FPCIT.NET: A WEB BASED ARCHIVE FOR USE WITH 123I IOFLUPANE." Nuclear Medicine Communications 26, no. 3 (March 2005): 294. http://dx.doi.org/10.1097/00006231-200503000-00111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Djang, D. S. W., M. J. R. Janssen, N. Bohnen, J. Booij, T. A. Henderson, K. Herholz, S. Minoshima, et al. "SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0." Journal of Nuclear Medicine 53, no. 1 (December 8, 2011): 154–63. http://dx.doi.org/10.2967/jnumed.111.100784.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Werner, Rudolf A., Charles Marcus, Sara Sheikhbahaei, Lilja B. Solnes, Jeffrey P. Leal, Yong Du, Steven P. Rowe, et al. "Visual and Semiquantitative Accuracy in Clinical Baseline 123I-Ioflupane SPECT/CT Imaging." Clinical Nuclear Medicine 44, no. 1 (January 2019): 1–3. http://dx.doi.org/10.1097/rlu.0000000000002333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Samardžić, T., R. Petrović, M. Relja, S. Telarović, and V. Miletić. "The achievements of I-123 ioflupane (DatSCAN) in a diagnosis of parkinsonism." Journal of the Neurological Sciences 333 (October 2013): e89. http://dx.doi.org/10.1016/j.jns.2013.07.581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ahmed, Anwar, Juebin Huang, Kun Chen, José M. Zubeldia, Jan Booij, and Vani Vijayakumar. "[123I]Ioflupane imaging in Caucasians and non-Caucasians: Are there any differences?" Journal of the Neurological Sciences 395 (December 2018): 159–63. http://dx.doi.org/10.1016/j.jns.2018.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Lloyd, Jim J., George Petrides, Paul C. Donaghy, Sean J. Colloby, Johannes Attems, John T. O'Brien, Gemma Roberts, and Alan J. Thomas. "A new visual rating scale for Ioflupane imaging in Lewy body disease." NeuroImage: Clinical 20 (2018): 823–29. http://dx.doi.org/10.1016/j.nicl.2018.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Tateno, F., S. Ryuji, A. Yousuke, T. Youhei, K. Masahiko, and O. Tuyoshi. "The relationship between lower urinary tractfunction and 123I-ioflupane scintigraphyin Parkinson’s disease." Journal of the Neurological Sciences 381 (October 2017): 1037. http://dx.doi.org/10.1016/j.jns.2017.08.2928.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Boeve, B., T. Ferman, M. Irfan, J. Aakre, E. St Louis, M. Silber, M. Tippmann-Peikert, et al. "Clinical, neuropsychiatric, and ioflupane SPECT imaging findings in REM sleep behavior disorder." Journal of the Neurological Sciences 357 (October 2015): e8. http://dx.doi.org/10.1016/j.jns.2015.08.104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Shibayama, H., K. Tokumoto, E. Fujisawa, H. Yano, K. Tajima, F. Katada, S. Sato, and T. Fukutake. "For effective utilization of dat-spect with 123i-ioflupane in clinical practice." Journal of the Neurological Sciences 357 (October 2015): e249. http://dx.doi.org/10.1016/j.jns.2015.08.868.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Covington, Matthew F., Scott Sherman, Denise Lewis, Hong Lei, Elizabeth Krupinski, and Phillip H. Kuo. "Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging." PLOS ONE 10, no. 7 (July 30, 2015): e0134457. http://dx.doi.org/10.1371/journal.pone.0134457.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Jenkins, Peter O., Sara De Simoni, Niall J. Bourke, Jessica Fleminger, Gregory Scott, David J. Towey, William Svensson, et al. "Stratifying drug treatment of cognitive impairments after traumatic brain injury using neuroimaging." Brain 142, no. 8 (June 14, 2019): 2367–79. http://dx.doi.org/10.1093/brain/awz149.

Full text

Abstract:

Abstract Cognitive impairment is common following traumatic brain injury. Dopaminergic drugs can enhance cognition after traumatic brain injury, but individual responses are highly variable. This may be due to variability in dopaminergic damage between patients. We investigate whether measuring dopamine transporter levels using 123I-ioflupane single-photon emission computed tomography (SPECT) predicts response to methylphenidate, a stimulant with dopaminergic effects. Forty patients with moderate-severe traumatic brain injury and cognitive impairments completed a randomized, double-blind, placebo-controlled, crossover study. 123I-ioflupane SPECT, MRI and neuropsychological testing were performed. Patients received 0.3 mg/kg of methylphenidate or placebo twice a day in 2-week blocks. Subjects received neuropsychological assessment after each block and completed daily home cognitive testing during the trial. The primary outcome measure was change in choice reaction time produced by methylphenidate and its relationship to stratification of patients into groups with normal and low dopamine transporter binding in the caudate. Overall, traumatic brain injury patients showed slow information processing speed. Patients with low caudate dopamine transporter binding showed improvement in response times with methylphenidate compared to placebo [median change = −16 ms; 95% confidence interval (CI): −28 to −3 ms; P = 0.02]. This represents a 27% improvement in the slowing produced by traumatic brain injury. Patients with normal dopamine transporter binding did not improve. Daily home-based choice reaction time results supported this: the low dopamine transporter group improved (median change −19 ms; 95% CI: −23 to −7 ms; P = 0.002) with no change in the normal dopamine transporter group (P = 0.50). The low dopamine transporter group also improved on self-reported and caregiver apathy assessments (P = 0.03 and P = 0.02, respectively). Both groups reported improvements in fatigue (P = 0.03 and P = 0.007). The cognitive effects of methylphenidate after traumatic brain injury were only seen in patients with low caudate dopamine transporter levels. This shows that identifying patients with a hypodopaminergic state after traumatic brain injury can help stratify the choice of cognitive enhancing therapy.

APA, Harvard, Vancouver, ISO, and other styles

45

Martinez-Murcia, F. J., J. M. Górriz, J. Ramírez, M. Moreno-Caballero, and M. Gómez-Río. "Parametrization of textural patterns in123I-ioflupane imaging for the automatic detection of Parkinsonism." Medical Physics 41, no. 1 (December 17, 2013): 012502. http://dx.doi.org/10.1118/1.4845115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Dibble, Elizabeth H., Don C. Yoo, Richard B. Noto, and Joseph H. Friedman. "Atypical Parkinsonian Syndromes With Very Poor Striatal Uptake on 123I-Ioflupane SPECT Imaging." Clinical Nuclear Medicine 40, no. 2 (February 2015): e152-e156. http://dx.doi.org/10.1097/rlu.0000000000000608.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Mihăilescu, Gabriela. "Essential tremor." Romanian Medical Journal 62, no. 4 (December 31, 2015): 357–62. http://dx.doi.org/10.37897/rmj.2015.4.5.

Full text

Abstract:

Essential tremor is a frequent disease, but rather often under-diagnosed, due to the fact that the patients with mild essential tremor don’t visit the neurologist, or due to some confusion in establishing the diagnosis in advanced stages of the disease. The clinical diagnosis is the most important, and is sustained today by imaging techniques such as Datscan using 123I-Ioflupane, used in the differential diagnosis between essential tremor and Parkinsonian syndromes. The precise and early diagnosis permit the specific, customized symptomatic treatment, taking care of al the particularities of every patient, and in case of no-response to medical treatment, neurosurgical methods are available, some of them very recent, some still in clinical trials, as well as the genetic studies in order to establish the etiology of the most frequent disease in the field of movement disorders.

APA, Harvard, Vancouver, ISO, and other styles

48

Lundeen, Tamara F., Matthew Covington, Elizabeth A. Krupinski, Ryan Avery, Hong Lei, Scott J. Sherman, and Phillip H. Kuo. "Accuracy of Dopamine Transporter Imaging with 123I-Ioflupane in Hispanic and Non-Hispanic Patients." Journal of Nuclear Medicine Technology 48, no. 2 (October 11, 2019): 154–57. http://dx.doi.org/10.2967/jnmt.119.231423.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Quattrone, Andrea, Rita Nisticò, Maurizio Morelli, Gennarina Arabia, Marianna Crasà, Basilio Vescio, Alessandro Mechelli, Giuseppe L. Cascini, and Aldo Quattrone. "Rest Tremor Pattern Predicts DaTscan ( ¹²³ I‐Ioflupane ) Result in Tremulous Disorders." Movement Disorders 36, no. 12 (September 28, 2021): 2964–66. http://dx.doi.org/10.1002/mds.28797.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

García-Gómez, F. J., D. García-Solís, F. J. Luis-Simón, V. A. Marín-Oyaga, F. Carrillo, P. Mir, and R. J. Vázquez-Albertino. "Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane." Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 32, no. 6 (November 2013): 350–56. http://dx.doi.org/10.1016/j.remnie.2013.09.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!